Prognostic and predictive markers in cancer

被引:34
作者
Conley, BA
Taube, SE
机构
[1] NCI, Aerodigest Canc Clin Res Sect, Med Oncol Clin Res Unit, Canc Res Ctr,DHHS,NIH, Bethesda, MD 20892 USA
[2] NCI, Canc Diagnosis Program, Div Canc Treatment & Diagnosis, DHHS,NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1155/2004/202031
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The elucidation of the human genome and advances in knowledge about molecular abnormalities, signaling pathways, influence of the local tissue milieu and the relevance of genetic polymorphisms offer hope of designing more effective, individualized cancer treatment plans. Although the scientific and medical literature is replete with reports of putative prognostic or predictive markers for cancer, few new diagnostics have been incorporated into routine clinical practice. Criteria are needed to a) identify markers that have the promise to be clinically useful; b) assess the best methodology for clinical evaluation of the markers in question and c) confirm or validate that using the marker adds useful information compared to using standard prognostic factors alone. This review presents a methodology for the clinical evaluation of putative prognostic and predictive markers in cancer, with considerations of pitfalls in the early evaluation, rationale for development and optimization of assay methodology, and examples of possible clinical trials for assessing the clinical utility of putative markers.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 39 条
[1]  
Albanell J, 2003, ADV EXP MED BIOL, V532, P253
[2]  
Ando Y, 2000, CANCER RES, V60, P6921
[3]   Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer [J].
Arteaga, CL .
BREAST CANCER RESEARCH, 2003, 5 (02) :96-100
[4]   An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].
Boye, J ;
Elter, T ;
Engert, A .
ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535
[5]  
Capdeville R, 2003, SEMIN HEMATOL, V40, P15
[6]  
Cascinu S, 2000, CLIN CANCER RES, V6, P2803
[7]   WHY PREDICTIVE INDEXES PERFORM LESS WELL IN VALIDATION STUDIES - IS IT MAGIC OR METHODS [J].
CHARLSON, ME ;
ALES, KL ;
SIMON, R ;
MACKENZIE, CR .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (12) :2155-2161
[8]   p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610 [J].
Grignon, DJ ;
Caplan, R ;
Sarkar, FH ;
Lawton, CA ;
Hammond, EH ;
Pilepich, MV ;
Forman, JD ;
Mesic, J ;
Fu, KK ;
Abrams, RA ;
Pajak, TF ;
Shipley, WU ;
Cox, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (02) :158-165
[9]   Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer [J].
Gryfe, R ;
Kim, H ;
Hsieh, ETK ;
Aronson, MD ;
Holowaty, EJ ;
Bull, SB ;
Redston, M ;
Gallinger, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (02) :69-77
[10]  
HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444